Drug intelligence / Profile preview

vinblastine + vincristine + prednisone + daunorubicin

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of vinblastine, vincristine, prednisone, and daunorubicin. This combination of drugs targets rapidly dividing cancer cells through different mechanisms. Vincristine and vinblastine are plant alkaloids that interfere with cell division by preventing microtubule formation. Daunorubicin is an anthracycline that prevents DNA replication in cancer cells. Prednisone is a corticosteroid that can kill cancer cells and help manage side effects of chemotherapy.

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNAGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on vinblastine + vincristine + prednisone + daunorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vinblastine + vincristine + prednisone + daunorubicin.

Explore the full profile